Immune thrombocytopenia following successful treatment of cancer in children.
A predisposition to developing immune thrombocytopenia (ITP) has not been reported in survivors of childhood cancer. We report a case series of childhood cancer survivors who developed an isolated thrombocytopenia in the presence of a normocellular bone marrow. Five children, two with endodermal sinus tumors and three with acute lymphoblastic leukemia, developed ITP at a median of 4 years (range: 0.2-8 years) after completion of therapy. We suggest the association of ITP in survivors of childhood malignancy may not be co-incidental as chemotherapy may cause persistent immune dysfunction.
Price
Victoria
V
Department of Pediatrics, Division of Hematology/Oncology, The Hospital for Sick Children, University of Toronto, Canada.
Barnes
Chris
C
Canning
Patricia
P
Blanchette
Victor
V
Greenberg
Mark
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects; D001854:Bone Marrow Cells / Q000473:pathology; D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D010976:Platelet Count; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood / Q000209:etiology* / Q000473:pathology; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D001215:Asparaginase; D002330:Carmustine; D011241:Prednisone; D003630:Daunorubicin